Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms EVEREST
- Sponsors AbbVie
- 27 Aug 2020 Status changed from active, no longer recruiting to completed.
- 03 Jun 2020 Planned End Date changed from 15 Mar 2020 to 15 Aug 2020.
- 03 Jun 2020 Planned primary completion date changed from 15 Mar 2020 to 15 Aug 2020.